County of Morrow, Ohio (MOR)
Aug 5, 2024 - MOR was delisted (reason: voluntary delisting)
18.96
+0.45 (2.43%)
Inactive · Last trade price on Aug 2, 2024

Company Description

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States.

It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.

The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2.

In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases.

MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma.

The company was founded in 1992 and is headquartered in Planegg, Germany.

County of Morrow, Ohio
MorphoSys AG logo
CountryUnited States
Founded1992
IPO DateMar 9, 1999
IndustryBiotechnology
SectorHealthcare
Employees524
CEOPh.D. Arkadius Pichota M.B.A.

Contact Details

Address:
Semmelweisstr. 7
Planegg, 2M 2M
United States
Phone49 89 89927-0

Stock Details

Ticker SymbolMOR
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001340243
CUSIP Number617760202
ISIN NumberUS6177602025
SIC Code9111

Key Executives

NamePosition
Arkadius Pichota M.B.A., Ph.D.Chief Executive Officer
Charlotte LohmannChief Legal and Human Resources Officer and Member of Management Board
Lukas GilgenChief Financial Officer
Dr. Tim Demuth M.D., Ph.D.Chief Research and Development Officer
Klaus De WallHead of Accounting and Tax
Dr. Margit UrbanHead of Discovery Alliances and Technologies
Dr. Julia Neugebauer Ph.D.Head of Investor Relations
Dr. Barbara Krebs-Pohl Ph.D.Chief Business Officer
Dr. Günter WellnhoferHead of Technical Operations
Dr. Harald WatzkaHead of Alliance Management

Latest SEC Filings

DateTypeTitle
Aug 5, 20246-KReport of foreign issuer
Aug 2, 2024SC TO-T/AFiling
Aug 1, 2024SC TO-T/AFiling
Jul 31, 2024SC TO-T/AFiling
Jul 30, 2024SC TO-T/AFiling
Jul 29, 2024SC TO-T/AFiling
Jul 25, 2024SC TO-T/AFiling
Jul 25, 202425Filing
Jul 18, 2024SC TO-T/AFiling
Jul 18, 20246-KReport of foreign issuer